SCHEMBL3752720

SCHEMBL3752720

O=C(c1ncco1)C1CCN(Cc2ccc3c(c2)OCO3)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.56
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SIGMAR1 Q99720 2/20 0.51
FABP1 P07148 1/20 0.51
FABP6 P51161 1/20 0.51
MCHR1 Q99705 3/20 0.50
LMNA P02545 2/20 0.50
PMP22 Q01453 1/20 0.50
USP2 O75604 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
CYP2D6 P10635 1/20 0.50
DRD2 P14416 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
NFKB1 P19838 1/20 0.50
SLC6A2 P23975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748338 0.85 FAAH (0.58) FAAHMCHR1CYP2D6KCNH2
SCHEMBL3747632 0.83 FAAH (0.58) FAAHSIGMAR1ALDH1A1KDM4E
SCHEMBL3751806 0.83 FAAH (0.58) FAAHMEN1KMT2ASIGMAR1KCNH2
SCHEMBL3748380 0.83 FAAH (0.58) FAAHKDM4E
SCHEMBL4659190 0.82 MEN1 (0.48) FAAHMEN1KMT2ASIGMAR1FABP1
SCHEMBL4184844 0.82 FAAH (0.72) FAAH
SCHEMBL3747939 0.82 FAAH (0.66) FAAHKMT2A
SCHEMBL3751195 0.82 FAAH (0.68) FAAHSIGMAR1MCHR1
SCHEMBL3749375 0.81 FAAH (0.67) FAAHKMT2A
SCHEMBL3752384 0.81 FAAH (0.67) FAAHSIGMAR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US claimed
EP-2023728-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2009-02-18 EP claimed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO claimed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA NV (BE) 2010-11-18 US disclosed
WO-2007140005-A2 OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292266-A1 Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, APEH FAAH 1/4885MEN1 4680/4885KMT2A 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.